MAPPharma
LEVADEX (TM) investigational orally inhaled migraine product candidate (MAP0004)
ir.mappharma.com/releasedetail.cfm?ReleaseID=385799
LEVADEX is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using MAP Pharmaceuticals' proprietary TEMPO(R) inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of DHE, a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.
Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation.
Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles.
LEVADEX (TM) investigational orally inhaled migraine product candidate (MAP0004)
ir.mappharma.com/releasedetail.cfm?ReleaseID=385799
LEVADEX is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using MAP Pharmaceuticals' proprietary TEMPO(R) inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of DHE, a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.
Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation.
Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles.